Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells

References

• Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3:781 - 790
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8ab T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2:255 - 260
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96:6879 - 6884
   PubMed Web of Science ®Google Scholar
• Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2001; 2:443 - 451
   PubMed Web of Science ®Google Scholar
• Radaev S, Rostro B, Brooks AG, Colonna M, Sun PD. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity 2001; 15:1039 - 1049
   PubMed Web of Science ®Google Scholar
• Watzl C. The NKG2D receptor and its ligands-recognition beyond the “missing self”?. Microbes Infect 2003; 5:31 - 37
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 2003; 61:335 - 343
   PubMed Web of Science ®Google Scholar
• Mistry AR, O'Callaghan CA. Regulation of ligands for the activating receptor NKG2D. Immunology 2007; 121:439 - 447
   PubMed Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA. Science 1999; 285:727 - 729
   PubMed Web of Science ®Google Scholar
• Stephens HA. MICA and MICB genes: can the enigma of their polymorphism be resolved?. Trends Immunol 2001; 22:378 - 385
   PubMed Web of Science ®Google Scholar
• Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol Rev 2006; 214:130 - 142
   PubMed Web of Science ®Google Scholar
• Hamerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr Opin Immunol 2005; 17:29 - 35
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 2001; 181:158 - 169
   PubMed Web of Science ®Google Scholar
• Siren J, Sareneva T, Pirhonen J, Strengell M, Veckman V, Julkunen I, et al. Cytokine and contact-dependent activation of natural killer cells by influenza A or Sendai virus-infected macrophages. J Gen Virol 2004; 85:2357 - 2364
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Kärre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985; 162:1745 - 1759
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Smyth MJ. NKG2D and cytotoxic effector function in tumor immune surveillance. Semin Immunol 2006; 18:176 - 185
   PubMed Web of Science ®Google Scholar
• Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, Novel MHC Class I-Related Molecules, Bind to CMV Glycoprotein UL16 and Stimulate NK Cytotoxicity through the NKG2D Receptor. Immunity 2001; 14:123 - 133
   PubMed Web of Science ®Google Scholar
• Maasho K, Opoku-Anane J, Marusina AI, Coligan JE, Borrego F. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol 2005; 174:4480 - 4484
   PubMed Web of Science ®Google Scholar
• Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger NK cells activation and costimulation. Nat Immunol 2002; 3:1150 - 1155
   PubMed Web of Science ®Google Scholar
• Wu J, Song Y, Bakker ABH, Bauer S, Spies T, Lanier LL, Phillips JH. An Activating Immunoreceptor Complex Formed by NKG2D and DAP10. Science 1999; 285:730 - 732
   PubMed Web of Science ®Google Scholar
• Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F, Coligan JE. The NKG2D receptor: immunobiology and clinical implications. Immunol Res 2008; 40:18 - 34
   PubMed Web of Science ®Google Scholar
• Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003; 4:557 - 564
   PubMed Web of Science ®Google Scholar
• Groh V, Anja B, El-Gabalawy H, Nelson JL, Thomas S. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. PNAS 2003; 100:9452 - 9457
   PubMed Web of Science ®Google Scholar
• Saikali P, Antel JP, Newcombe J, Chen Z, Freedman M, Blain M, et al. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J Neurosci 2007; 27:1220 - 1228
   PubMed Web of Science ®Google Scholar
• Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004; 21:357 - 366
   PubMed Web of Science ®Google Scholar
• Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 2005; 6:938 - 945
   PubMed Web of Science ®Google Scholar
• Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004; 20:757 - 767
   PubMedGoogle Scholar
• Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, Schmitz J, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004; 21:367 - 377
   PubMed Web of Science ®Google Scholar
• Martin-Pagola A, Ortiz L, Perez de Nanclares G, Vitoria JC, Castano L, Bilbao JR. Analysis of the expression of MICA in small intestinal mucosa of patients with celiac disease. J Clin Immunol 2003; 23:498 - 503
   PubMed Web of Science ®Google Scholar
• Stepniak D, Koning F. Celiac disease—sandwiched between innate and adaptive immunity. Hum Immunol 2006; 67:460 - 468
   PubMed Web of Science ®Google Scholar
• Caillat-Zucman S. How NKG2D ligands trigger autoimmunity?. Hum Immunol 2006; 67:204 - 207
   PubMed Web of Science ®Google Scholar
• Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7− CD28− T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996; 97:2027 - 2037
   PubMed Web of Science ®Google Scholar
• Schmidt D, Martens PB, Weyand CM, Goronzy JJ. The repertoire of CD4+ CD28− T cells in rheumatoid arthritis. Mol Med 1996; 2:608 - 618
   PubMed Web of Science ®Google Scholar
• Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 1997; 40:1106 - 1114
   PubMed Web of Science ®Google Scholar
• Boles KS, Barchet W, Diacovo T, Cella M, Colonna M. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood 2005; 106:779 - 786
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734 - 738
   PubMed Web of Science ®Google Scholar
• Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via downregulating NKG2D expression. Cell Immunol 2006; 239:22 - 30
   PubMed Web of Science ®Google Scholar
• Wiemann K, Mittrucker HW, Feger U, Welte SA, Yokoyama WM, Spies T, et al. Systemic NKG2D downregulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005; 175:720 - 729
   PubMed Web of Science ®Google Scholar
• Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005; 6:928 - 937
   PubMed Web of Science ®Google Scholar
• Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E, Held W. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005; 106:1711 - 1717
   PubMed Web of Science ®Google Scholar
• Kwong KY, Baskar S, Zhang H, Mackall CL, Rader C. Generation, Affinity Maturation, and Characterization of a Human Anti-Human NKG2D Monoclonal Antibody with Dual Antagonistic and Agonistic Activity. J Mol Biol 2008; 384:1143 - 1156
   PubMed Web of Science ®Google Scholar
• Raum T, Gruber R, Riethmuller G, Kufer P. Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens. Cancer Immunol Immunother 2001; 50:141 - 150
   PubMed Web of Science ®Google Scholar
• Krinner EM, Hepp J, Hoffmann P, Bruckmaier S, Petersen L, Petsch S, et al. A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. Protein Eng Des Sel 2006; 19:461 - 470
   PubMed Web of Science ®Google Scholar